Landmark Trial Tests Whether Chemotherapy Can Be Spared in High-Risk Early Breast Cancer
The new phase 3 RxFINE-Low trial will test whether patients with low genomic risk but high anatomic risk early-stage breast ...
The new phase 3 RxFINE-Low trial will test whether patients with low genomic risk but high anatomic risk early-stage breast ...
A two-year randomized controlled trial in Shanghai found that nightly 0.10 percent atropine eye drops significantly slowed myopia progression in ...
A randomized trial combining in situ viral imaging and mass spectrometry shows that first-line dolutegravir/lamivudine therapy penetrates lymph node tissue ...
A controversial clinical trial has once again thrust homeopathy into the center of a scientific firestorm. In a prospective, randomized, ...
A phase 2 trial found that ultra-low-dose radiation therapy delivered in one or two sessions relieved painful bone lesions in ...
Five-year results from the NRG-GU003 Phase III trial show that a 25-fraction, five-week postoperative radiation schedule achieved biochemical control and ...
A randomized controlled trial published in Nature Communications reports that the oral CDK7 inhibitor samuraciclib combined with fulvestrant improved clinical ...
UChicago Medicine has launched a first-of-its-kind investigator-initiated clinical trial of a fully on-site manufactured T-cell receptor therapy engineered to target ...
A seven-year prospective trial shows that oral S-1 plus cisplatin preserves overall 5-FU exposure and manageable toxicity in cancer patients ...
A randomized sham-controlled trial found that embodiment-based psychotherapy, with or without concurrent tDCS, greatly improved interoceptive awareness and depressive symptoms ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine